North America Muscle Relaxant Drugs Market Size, Share & Industry Trends Analysis Report By Drug Type, By Route of Administration (Oral and Injectable), By Distribution Channel, By Country and Growth Forecast, 2023 - 2029

The North America Muscle Relaxant Drugs Market should witness market growth of 3.6% CAGR during the forecast period (2023-2029).

The elderly population is highly susceptible to muscle pain; consequently, the aging population is the primary market driver. Additionally, the increase in surgical procedures has bolstered the market. The rising incidence of chronic back problems and the increase in the number of back surgeries are major factors propelling the growth of the market. In addition, the increasing prevalence of musculoskeletal disorders and growing consumer awareness of their management and treatment are anticipated to be the driving forces behind the expansion of the market.

Muscle relaxant medications treat muscle tension, spasm, and hyperreflexia. On the market, there are two categories of muscle relaxants which are centrally acting muscle relaxants and directly acting muscle relaxants. Neuromuscular blocking compounds are also known as direct-acting muscle relaxants. These have no activity in the central nervous system and interfere with neuronal transmission at the neuromuscular junction end plate.

One of the most prevalent chronic illnesses in Canada is back pain. Back pain affects four out of five people at some point. However, it often strikes people between the ages of 30 and 50. Men and women have back issues on an equal basis. However, the reason for back pain is not always apparent; in 85% to 90% of people with back pain, no particular cause can be found. As a result, many people with neck or back discomfort will resort to muscle relaxants for relief or as a form of treatment, helping the market in North America to grow.

The US market dominated the North America Muscle Relaxant Drugs Market by Country in 2022 thereby, achieving a market value of $1,288.8 Million by 2029. The Canada market is exhibiting CAGR of 5.6% during (2023-2029). Additionally, The Mexico market would experience a CAGR of 5.3% during (2023-2029).

Based on Drug Type, the market is segmented into Skeletal, Neuromuscular Blocking Agents and Facial Muscle Relaxant Drugs. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amneal Pharmaceuticals, Inc., Ipsen Pharma Biotech SAS, Merz Pharma GmbH & Co. KGaA, Mallinckrodt PLC, Teva Pharmaceuticals Industries Ltd., Eisai Co., Ltd., Endo International PLC, Vertical Pharmaceuticals, LLC, SteriMax Inc., and Metacel Pharmaceuticals, LLC.

Scope of the Study

By Drug Type

• Skeletal
• Neuromuscular Blocking Agents
• Facial Muscle Relaxant Drugs

By Route of Administration

• Oral
• Injectable

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies

By Country

• US
• Canada
• Mexico
• Rest of North America

Key Market Players

List of Companies Profiled in the Report:

• Amneal Pharmaceuticals, Inc.
• Ipsen Pharma Biotech SAS
• Merz Pharma GmbH & Co. KGaA
• Mallinckrodt PLC
• Teva Pharmaceuticals Industries Ltd.
• Eisai Co., Ltd.
• Endo International PLC
• Vertical Pharmaceuticals, LLC
• SteriMax Inc.
• Metacel Pharmaceuticals, LLC

Unique Offerings

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free